Oncolytics Biotech Inc. Announces Corporate Changes and Shareholder Updates

CALGARY, March 17, 2026 – Oncolytics Biotech Inc. (“Oncolytics” or the “Company”) has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) detailing significant corporate changes that could have a material impact on shareholders and the market value of the Company’s shares. The filing provides a comprehensive update on the Company’s change in jurisdiction, amendments to corporate governing documents, and important shareholder rights and procedures.

Key Highlights of the Report

• Corporate Continuance: Oncolytics Biotech Inc. has transitioned from Alberta, Canada to British Columbia, Canada, as part of a broader strategy. This process included the adoption of new Notice of Articles and Articles, effective following the Certificate of Continuation. The move is intended to improve corporate governance and align with best practices in the industry.
• Amendments to Articles and Share Structure: The Company has adopted new Articles of Incorporation. The authorized share structure consists of common shares with no par value, and the new Articles outline comprehensive rules regarding the issuance, transfer, and alteration of shares. Notably, there is no maximum number of common shares that can be issued, giving the Company significant flexibility for future fundraising and acquisitions. This could be price sensitive as it allows for potential equity raises or strategic transactions.
• Change in Trading Venue Anticipated: The filing references the anticipated timing of the Company’s common shares commencing trading on Nasdaq as a Nevada corporation. Such a move, if completed, could increase visibility, liquidity, and access to new pools of capital, which may positively impact the stock’s valuation.
• Material Modifications to Shareholder Rights: The new Articles and Notice of Articles introduce changes that may affect the rights of current security holders, including procedures for the calling and conduct of shareholder meetings, nomination of directors, and the possible alteration of share structure by ordinary resolution. These changes are fully described in the management information circular/prospectus filed with the SEC.
• Advance Notice Provisions for Director Nominations: Shareholders wishing to nominate individuals for election to the board are now subject to strict advance notice provisions. Nominations must be submitted in writing and received by the corporate secretary within specified timeframes before annual or special meetings. The notice must provide detailed information about the nominee and the nominating shareholder, including beneficial ownership, employment history, and relevant agreements or arrangements. Failure to comply will result in exclusion from the meeting agenda. This provision is important for any shareholders seeking to influence board composition and could affect activist campaigns or governance changes.
• Shareholder Meetings and Voting Procedures: The new Articles clarify the types of business that can be conducted at annual and special meetings, the notice requirements, and the rules for electronic meetings and voting. “Special business” is defined more narrowly, and only business specified in the notice of meeting can be transacted, except in limited exceptions. Shareholders are also reminded of the exclusive use of the advance notice procedure for director nominations.
• Potential for Share Issuances and Capital Structure Changes: The board is authorized to issue, allot, sell, or otherwise dispose of unissued shares (including those held by the Company) at their discretion, subject to applicable laws and the rights of existing holders. The Company may also pay commissions or discounts to facilitate share purchases, and all shares must be fully paid before issuance. The Articles allow for share buybacks, redemptions, or acquisitions, but restrict the Company from voting or receiving dividends on those shares while held in treasury.
• Shareholder Protections and Consent Rights: The Articles require that rights attached to any class or series of shares cannot be prejudiced or altered without consent from the affected shareholders. Changes to the authorized share structure, class rights, or other significant governance alterations generally require an ordinary resolution, ensuring shareholder involvement in major decisions.
• Other Governance Updates: The Articles detail procedures for notice of meetings, record dates, quorum, electronic voting, adjournments, and the treatment of special business. They also outline the process for dividend declarations, borrowing powers, indemnification of directors and officers, and the inspection of accounting records.
• Forward-Looking Statements and Risk Factors: The filing contains numerous forward-looking statements related to the timing and completion of the Company’s domestication and Nasdaq listing. Investors are cautioned that actual results may differ materially due to various risks and uncertainties, including those detailed in the Company’s public filings and management circular.

Important Information for Shareholders

• Shareholder Value Impact: The increased flexibility in share issuance and the potential Nasdaq listing are potentially price-sensitive events. They could lead to capital raises, strategic partnerships, or M&A activity, which may affect dilution, control, and valuation.
• Governance and Rights: The new Articles empower the board but also include measures to safeguard shareholder rights related to class protections, director nominations, and meeting procedures. Shareholders should review the advance notice requirements carefully if they intend to participate in board elections or propose business at meetings.
• Transparency and Compliance: All significant changes, including the full text of the Notice of Articles and Articles, are available as exhibits to the SEC filing. Shareholders are encouraged to read these documents and the related management circular/prospectus for a full understanding of their rights and obligations under the new governance framework.

Potential Share Price Movements

The combination of a change in jurisdiction, anticipated U.S. listing, and new share issuance flexibility is likely to be viewed as a significant development by the market. Investors may react positively to the enhanced governance and access to new capital, or negatively if they are concerned about potential dilution or changes in control. The adoption of robust advance notice provisions may also influence shareholder activism and board composition.

Conclusion

Oncolytics Biotech Inc. has implemented major corporate and governance changes that could materially affect shareholder value and future strategic direction. Key issues for investors include the flexibility for future share issuances, the specifics of the new Articles and Notice of Articles, the move towards a potential Nasdaq listing, and strengthened procedures around director nominations and shareholder meetings. All investors are advised to review the new corporate documents and monitor further filings for additional updates on the Company’s transformation.

Disclaimer: This article summarizes key points from Oncolytics Biotech Inc.’s Form 8-K and related filings. It does not constitute investment advice. Investors should review the full filings available via the SEC and consult professional advisors before making investment decisions. Forward-looking statements are subject to risks, and actual outcomes may differ materially from those described.

View ONCOLYTICS BIOTECH INC Historical chart here